Amanta Healthcare Limited (AMANTA) — Announcement | 8 August 2026(2 announcements)

Amanta Healthcare reported Q1 FY27 revenue of INR69 crores, up 5% YoY with a stable 22% EBITDA margin, driven by SteriPort expansion and captive solar savings. SteriPort Line 3 is set to begin commercial production in the last week of August 2026 after FDA approval on August 6, targeting INR110-120 crores annualized revenue. The SVP facility is scheduled for commissioning in Q4 FY27, contributing 20% of FY26 revenue. Capital expenditures of INR90 crores and INR30 crores are underway for SteriPort Line 3 and SVP respectively, with incremental ROCE of 16-17% and 14-15%. EBITDA is projected at INR70 crores, interest expense to decline annually, and working capital cycle to improve to 120 days by reducing export quarantine impact. The company aims for 1000 crores revenue in 4-5 years, with 60-70% of SVP revenue from advanced markets like the UK, EU, Canada, and Australia. Gross margins faced pressure from 70-80% polymer price spikes, partially offset by INR1.50 price hikes, with full absorption expected over two quarters. Long-term growth focuses on sterile dosage forms, inhalation products, and ophthalmics, supported by a pipeline of 20 products including one inhalation product commercializing mid-September 2026.

Amanta Healthcare Limited disclosed its Monitoring Agency Report for the quarter ended June 30, 2026, confirming compliance with SEBI regulations regarding utilization of IPO proceeds. The report verifies that funds were allocated to capital expenditure for SteriPort and SVP manufacturing lines, general corporate purposes, and that all statutory approvals were secured. No deviations or material risks were identified, and the company confirmed adherence to the offer document’s objectives. The filing reinforces transparency in fund deployment, which is critical for investor confidence in the IPO’s execution.